CUTISS AG raises CHF 7.25M in Series A financing

The startup of the project denovoSkin, CUTISS AG raises CHF 7.25 millions in the Series A financing round.

CUTISS AG’s lead product denovoSkin™ has successfully completed Phase I in pediatric patients and is recruiting in multi-centric Phase II studies financed by Wyss Zurich. This series A financing round is succeeding a CHF 1 million convertible loan previously provided to the company by the UZH Life Sciences Fund, and now converted.

Recommended News

Sign up for our newsletter!

For newsletter distribution, your email address will be processed by a GDPR-certified service provider. Further information can be found in our privacy policy.